ToxicologyA comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning☆
Introduction
Physostigmine, a short-acting acetylcholinesterase inhibitor, increases synaptic acetylcholine concentrations and can overcome the postsynaptic muscarinic receptor blockade produced by anticholinergic agents. As a tertiary amine, it can pass freely into the central nervous system (CNS) and reverse both central and peripheral anticholinergic effects.
Physostigmine has been shown to be effective and safe when used to treat anticholinergic poisoning.1, 2, 3, 4, 5, 6, 7, 8, 9, 10 It was neither consistently effective nor safe when used as an antidote for undifferentiated drug-induced coma and tricyclic antidepressant (TCA) poisoning.5, 6, 10, 11, 12, 13, 14, 15, 16 Although seizures were more common than asystole when physostig-mine was used for patients with TCA poisoning,10, 11, 14, 15 the latter occurrence has led some to categorically dismiss physostigmine as a treatment option when overdose with TCAs is known or suspected.16, 17, 18
In 1997, US poison centers reported that only 2% of more than 7,000 patients treated in health care facilities with moderate to severe effects from anticholinergic agents other than TCAs received physostigmine.19 Fear of potential toxicity is probably responsible for its apparent current underutilization in this setting. Although physostigmine remains the most rational treatment for anticholinergic poisoning, benzodiazepines have been recommended as the preferred therapy for agitation and delirium.18, 20 We report our experience with physostigmine and benzodiazepines for the treatment of anticholinergic agitation and delirium.
Section snippets
Materials and Methods
Patients with a diagnosis of anticholinergic poisoning (International Classification of Diseases–ninth revision , code 971.1) were identified by reviewing toxicology consultations and discharge diagnoses at the University of Massachusetts Medical Center from April 1986 through July 1997.
Those who had agitation or delirium and were treated with physostigmine, benzodiazepines, or both were included in the study. Data abstracted from the medical record included patient demographics; drug exposure;
Results
Seventy-one patients with a diagnosis of anticholinergic poisoning were identified. Sixteen patients were excluded because they did not receive physostigmine or benzodiazepines. Three patients were excluded because they were subsequently determined not to have anticholinergic poisoning. Of the remaining 52 patients, 45 (86%) were treated with physostigmine and 26 (50%) with benzodiazepines. Additional sedating agents (eg, haloperidol) were used to control agitation in 4 (8%) patients.
Median age
Discussion
We found physostigmine to be more effective than benzodiazepines for the control of agitation and reversal of CNS stimulation and delirium associated with anticholinergic poisoning. Results were similar when physostigmine and benzodiazepines were compared as initial therapy, at separate times in the same patient, or using the blinded abstractor’s data. Although the incidence and time of initial relapse was similar between patients treated with either drug, those treated with physostigmine had
References (23)
- et al.
Physostigmine reversal of scopolamine delirium in obstetric patients
Am J Obstet Gynecol.
(1973) - et al.
Physostigmine treatment of anticholinergic poisoning
JACEP.
(1976) - et al.
Physostigmine—its use and abuse
JACEP.
(1976) - et al.
Asystole complicating physostigmine treatment of tricyclic antidepressant overdose
Ann Emerg Med.
(1980) As the pendulum swings: the saga of physostigmine [editorial]
J Emerg Med.
(1991)- et al.
1997 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System
Am J Emerg Med.
(1998) - et al.
Safety evaluation and confidence intervals when the number of observed events is small or zero
Ann Emerg Med.
(1997) - et al.
Chart reviews in emergency medicine research: where are the methods?
Ann Emerg Med.
(1996) - et al.
The treatment of scopolamine-induced delirium with physostigmine
Clin Pharmacol Ther.
(1967) - et al.
Reversal of postoperative reactions to scopolamine with physostigmine
Anesth Analg Curr Res.
(1973)
Central anticholinergic syndrome in anesthetic practice
Acta Anaesthesiol Belg.
Cited by (183)
The Management of Agitated Toxidromes
2022, Emergency Medicine Clinics of North AmericaThe Use of Physostigmine in the Diagnosis and Treatment of Anticholinergic Toxicity After Olanzapine Overdose: Literature Review and Case Report
2021, Journal of the Academy of Consultation-Liaison PsychiatryDhatura: Nutritional, phytochemical, and pharmacological properties
2024, Harvesting Food from WeedsPart I: Case series: Acute management of prescription and nonprescription drug overdoses
2024, JACCP Journal of the American College of Clinical PharmacyRivastigmine for the management of anticholinergic delirium
2024, Clinical ToxicologyDelirium secondary to anticholinergics
2024, Drug and Therapeutics Bulletin
- ☆
Address for reprints: Michael J. Burns, MD, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215; 617-667-5198; E-mail[email protected] .